Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total operating revenue | -9.31%617.2M | -16.66%424.68M | -15.97%287.17M | 0.05%154.59M | 3.79%680.56M | 0.29%509.6M | 2.06%341.76M | -8.21%154.51M | -18.84%655.69M | -15.33%508.12M |
Operating revenue | -9.31%617.2M | -16.66%424.68M | -15.97%287.17M | 0.05%154.59M | 3.79%680.56M | 0.29%509.6M | 2.06%341.76M | -8.21%154.51M | -18.84%655.69M | -15.33%508.12M |
Other operating revenue | ---- | ---- | 6.03%37.19M | ---- | ---- | ---- | -7.64%35.08M | ---- | -18.36%70.01M | ---- |
Total operating cost | -10.14%633.11M | -17.36%437.76M | -16.74%293.58M | -0.92%157.76M | -0.20%704.56M | -2.64%529.69M | 0.57%352.6M | -7.35%159.23M | -14.29%706M | -10.42%544.06M |
Operating cost | -10.83%440.61M | -20.38%296.45M | -20.55%196.87M | -2.22%106.1M | 1.33%494.13M | -1.30%372.33M | 1.85%247.79M | -8.11%108.5M | -17.11%487.64M | -13.36%377.24M |
Operating tax surcharges | -15.82%11.44M | -21.11%7.95M | -21.76%5.42M | -19.30%3.04M | 0.46%13.59M | -5.10%10.08M | -2.98%6.93M | 8.40%3.76M | -30.80%13.53M | -28.75%10.63M |
Operating expense | -18.40%57.83M | -22.23%44.44M | -18.01%32.4M | -19.26%16.76M | -8.05%70.87M | -10.31%57.14M | -3.57%39.52M | -6.43%20.76M | -10.69%77.08M | -3.35%63.7M |
Administration expense | -2.78%110.13M | -1.53%79.47M | 2.02%52.9M | 24.95%28.77M | -1.19%113.28M | -3.67%80.71M | -2.32%51.85M | -7.92%23.03M | -0.81%114.64M | 2.03%83.79M |
Financial expense | 3.24%13.1M | 0.03%9.44M | -8.07%5.98M | -2.59%3.1M | -3.26%12.69M | 8.53%9.44M | 6.76%6.5M | 1.46%3.18M | -6.10%13.12M | -3.17%8.7M |
-Interest expense (Financial expense) | -2.57%9.82M | -3.24%7.37M | -12.32%4.71M | -9.82%2.32M | --10.08M | -4.14%7.62M | 3.11%5.37M | -4.93%2.58M | ---- | 8.14%7.95M |
-Interest Income (Financial expense) | 40.64%-325.21K | 34.37%-278.47K | 22.12%-193.32K | 31.51%-112.17K | ---547.9K | 71.75%-424.33K | 56.05%-248.22K | 48.15%-163.79K | ---- | -72.10%-1.5M |
Credit Impairment Loss | -384.03%-44.24M | 200.01%750.22K | 200.01%750.22K | ---- | 63.61%-9.14M | -30.97%-750.18K | -30.97%-750.18K | ---- | -1,680.94%-25.12M | -954.33%-572.8K |
Asset Impairment Loss | 140.28%495.17K | ---- | ---- | ---- | -655.46%-1.23M | ---- | ---- | ---- | 81.21%-162.71K | ---- |
Other net revenue | -255.77%-23.69M | 1,071.38%19.2M | 12,937.80%9.17M | 1,051.34%5.68M | 206.41%15.21M | -91.93%1.64M | -105.11%-71.44K | 1,405.59%493.14K | -190.14%-14.3M | 1,087.58%20.3M |
Invest income | 5,128.76%11.89M | 43,953.60%11.75M | 21,533.24%2.7M | -53.78%9.26K | -1,246.41%-236.41K | -30.66%26.67K | -52.26%12.5K | 52.31%20.03K | -94.97%20.62K | -92.05%38.47K |
-Including: Investment income associates | 5,128.76%11.89M | 43,953.60%11.75M | 21,533.24%2.7M | -53.78%9.26K | -1,246.41%-236.41K | -30.66%26.67K | -52.26%12.5K | 52.31%20.03K | -94.97%20.62K | -92.05%38.47K |
Asset deal income | -72.55%6.44M | 15,266.84%6.43M | 21,005.76%5.64M | 20,951.24%5.61M | 169.64%23.45M | -99.78%41.86K | -3.43%26.72K | 40.43%26.63K | -45.26%8.7M | 96,762.84%18.84M |
Other revenue | -27.01%1.73M | -88.63%263.94K | -87.73%78.45K | -86.09%62.1K | 4.44%2.37M | 16.81%2.32M | -66.64%639.53K | --446.48K | 23.44%2.27M | 52.92%1.99M |
Operating profit | -351.04%-39.61M | 133.16%6.12M | 125.31%2.76M | 159.33%2.51M | 86.41%-8.78M | -18.01%-18.45M | 23.89%-10.91M | -20.81%-4.23M | -117,297.38%-64.6M | -182.68%-15.64M |
Add:Non operating Income | -88.58%2.47M | -66.23%76.72K | -77.90%42.78K | -93.18%7.7K | 1,778.66%21.61M | -44.59%227.18K | -45.72%193.61K | 12.45%112.88K | -86.83%1.15M | -46.07%410.02K |
Less:Non operating expense | -48.59%497.62K | 95.44%455.24K | 437.53%277.36K | -0.29%45.2K | -67.16%968.01K | 9.99%232.94K | -90.19%51.6K | 103.00%45.33K | 882.00%2.95M | -4.42%211.78K |
Total profit | -417.38%-37.64M | 131.10%5.74M | 123.47%2.53M | 159.39%2.47M | 117.86%11.86M | -19.56%-18.46M | 25.76%-10.77M | -21.60%-4.16M | -881.91%-66.4M | -209.21%-15.44M |
Less:Income tax cost | -230.37%-6.01M | 190.61%108.97K | 190.61%108.97K | 22.64%302.14K | 341.82%4.61M | -155.64%-120.26K | 72.15%-120.26K | -62.78%246.38K | -132.55%-1.9M | -91.69%216.14K |
Net profit | -536.17%-31.63M | 130.71%5.63M | 122.71%2.42M | 149.21%2.17M | 111.25%7.25M | -17.14%-18.34M | 24.34%-10.65M | -7.92%-4.41M | -2,544.11%-64.49M | -106.14%-15.65M |
Net profit from continuing operation | -536.17%-31.63M | 130.71%5.63M | 122.71%2.42M | 149.21%2.17M | 111.25%7.25M | -17.14%-18.34M | 24.34%-10.65M | -7.92%-4.41M | -2,544.11%-64.49M | -106.14%-15.65M |
Net profit of parent company owners | -536.17%-31.63M | 130.71%5.63M | 122.71%2.42M | 149.21%2.17M | 111.25%7.25M | -17.14%-18.34M | 24.34%-10.65M | -7.92%-4.41M | -2,544.11%-64.49M | -106.14%-15.65M |
Earning per share | ||||||||||
Basic earning per share | -536.84%-0.0581 | 130.56%0.0103 | 122.45%0.0044 | 149.38%0.004 | 111.23%0.0133 | -17.42%-0.0337 | 24.03%-0.0196 | -8.00%-0.0081 | -2,566.67%-0.1184 | -106.47%-0.0287 |
Diluted earning per share | -536.84%-0.0581 | 130.56%0.0103 | 122.45%0.0044 | 149.38%0.004 | 111.23%0.0133 | -17.42%-0.0337 | 24.03%-0.0196 | -8.00%-0.0081 | -2,566.67%-0.1184 | -106.47%-0.0287 |
Other composite income | ||||||||||
Total composite income | -536.17%-31.63M | 130.71%5.63M | 122.71%2.42M | 149.21%2.17M | 111.25%7.25M | -17.14%-18.34M | 24.34%-10.65M | -7.92%-4.41M | -2,544.11%-64.49M | -106.14%-15.65M |
Total composite income of parent company owners | -536.17%-31.63M | 130.71%5.63M | 122.71%2.42M | 149.21%2.17M | 111.25%7.25M | -17.14%-18.34M | 24.34%-10.65M | -7.92%-4.41M | -2,544.11%-64.49M | -106.14%-15.65M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
Auditor | Sichuan Huaxin (Group) Accounting Firm (Special General Partnership) | -- | -- | -- | Sichuan Huaxin (Group) Accounting Firm (Special General Partnership) | -- | -- | -- | Sichuan Huaxin (Group) Accounting Firm (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.